Samson, Susan L. http://orcid.org/0000-0002-8159-7093
Gu, Feng
Feldt-Rasmussen, Ulla
Zhang, Shaoling
Yu, Yerong
Witek, Przemysław
Kalra, Pramila
Pedroncelli, Alberto M.
Pultar, Philippe
Jabbour, Nadine
Paul, Michaela
Bolanowski, Marek
Clinical trials referenced in this document:
Documents that mention this clinical trial
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
https://doi.org/10.1007/s11102-021-01161-4
Funding for this research was provided by:
Novartis Pharma AG
Article History
Accepted: 9 June 2021
First Online: 18 July 2021
Declarations
:
: SS: Advisor for Novartis, Corcept, Chiasma. UF-R: Lecture fees from Novartis, Ipsen, Novo Nordisk, Pfizer. PW: Lecture fees from Novartis, Ipsen, Pfizer, Sanofi-Aventis, Elli-Lilly, Boehringer Ingelheim. PK: Participated in advisory board meetings of Novo Nordisk, Novartis, Eli Lilly. AMP, PP, NJ, MP: Employees of Novartis Pharmaceuticals Corporation/Novartis Pharma AG. MB: Lecture fees from Ipsen, Pfizer, Novartis. FG, SZ, YY: Nothing to disclose.
: The study was conducted in accordance with the Declaration of Helsinki, with an independent ethics committee/institutional review board at each site approving the study protocol.
: All patients provided written informed consent before participation.